Rigel Pharmaceuticals Inc... (RIGL)
Rigel Pharmaceuticals Statistics
Share Statistics
Rigel Pharmaceuticals has 17.86M shares outstanding. The number of shares has increased by 1.74% in one year.
| Shares Outstanding | 17.86M |
| Shares Change (YoY) | 1.74% |
| Shares Change (QoQ) | 1.41% |
| Owned by Institutions (%) | 0.01% |
| Shares Floating | 17.38M |
| Failed to Deliver (FTD) Shares | 2.1K |
| FTD / Avg. Volume | 0.86% |
Short Selling Information
The latest short interest is 456.92K, so 2.59% of the outstanding shares have been sold short.
| Short Interest | 456.92K |
| Short % of Shares Out | 2.59% |
| Short % of Float | 2.65% |
| Short Ratio (days to cover) | 1.41 |
Valuation Ratios
The PE ratio is 16.91 and the forward PE ratio is 18.78. Rigel Pharmaceuticals's PEG ratio is -0.1.
| PE Ratio | 16.91 |
| Forward PE | 18.78 |
| PS Ratio | 1.65 |
| Forward PS | 1 |
| PB Ratio | 89.93 |
| P/FCF Ratio | 9.41 |
| PEG Ratio | -0.1 |
Enterprise Valuation
Rigel Pharmaceuticals has an Enterprise Value (EV) of 298.9M.
| EV / Sales | 1.67 |
| EV / EBITDA | 10.48 |
| EV / EBIT | 9.5 |
| EV / FCF | 9.51 |
Financial Position
The company has a current ratio of 2.13, with a Debt / Equity ratio of 18.24.
| Current Ratio | 2.13 |
| Quick Ratio | 2.04 |
| Debt / Equity | 18.24 |
| Debt / EBITDA | 2.1 |
| Debt / FCF | 1.91 |
| Interest Coverage | 3.06 |
Financial Efficiency
Return on Equity is 531.78% and Return on Invested Capital is 21.28%.
| Return on Equity | 531.78% |
| Return on Assets | 10.66% |
| Return on Invested Capital | 21.28% |
| Revenue Per Employee | $1.11M |
| Profits Per Employee | $107.93K |
| Employee Count | 162 |
| Asset Turnover | 1.09 |
| Inventory Turnover | 3.11 |
Taxes
| Income Tax | 881K |
| Effective Tax Rate | 4.8% |
Stock Price Statistics
The stock price has increased by 41.56% in the last 52 weeks. The beta is 1.32, so Rigel Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.32 |
| 52-Week Price Change | 41.56% |
| 50-Day Moving Average | 20.33 |
| 200-Day Moving Average | 16.81 |
| Relative Strength Index (RSI) | 39.76 |
| Average Volume (20 Days) | 243.36K |
Income Statement
In the last 12 months, Rigel Pharmaceuticals had revenue of 179.28M and earned 17.48M in profits. Earnings per share was 0.99.
| Revenue | 179.28M |
| Gross Profit | 160.63M |
| Operating Income | 24.19M |
| Net Income | 17.48M |
| EBITDA | 28.51M |
| EBIT | 26.28M |
| Earnings Per Share (EPS) | 0.99 |
Balance Sheet
The company has 56.75M in cash and 59.97M in debt, giving a net cash position of -3.22M.
| Cash & Cash Equivalents | 56.75M |
| Total Debt | 59.97M |
| Net Cash | -3.22M |
| Retained Earnings | -1.39B |
| Total Assets | 163.98M |
| Working Capital | 71.8M |
Cash Flow
In the last 12 months, operating cash flow was 31.47M and capital expenditures -36K, giving a free cash flow of 31.43M.
| Operating Cash Flow | 31.47M |
| Capital Expenditures | -36K |
| Free Cash Flow | 31.43M |
| FCF Per Share | 1.79 |
Margins
Gross margin is 89.6%, with operating and profit margins of 13.49% and 9.75%.
| Gross Margin | 89.6% |
| Operating Margin | 13.49% |
| Pretax Margin | 10.24% |
| Profit Margin | 9.75% |
| EBITDA Margin | 15.9% |
| EBIT Margin | 13.49% |
| FCF Margin | 17.53% |
Dividends & Yields
RIGL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 5.91% |
| FCF Yield | 10.63% |
Analyst Forecast
The average price target for RIGL is $25, which is 44.8% higher than the current price. The consensus rating is "Hold".
| Price Target | $25 |
| Price Target Difference | 44.8% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Jun 27, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 27, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -8.64 |
| Piotroski F-Score | 7 |